Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Fonkozomib 3.5mg powder for injection

Ferron Par Pharmaceuticals

Ingredients in every vial

Bortezomib 3.5 mg

Each package contains

1 vial of 3.5 mg

Dosage form

Powder for injection

Dosage formPowder for injection

Flavour

None

W.H.O. classification

L01X
L01X

A.T.C. Level 1

Anatomical Main group

L - Antineoplastic and immunomodulating agents
L01X

A.T.C. Level 2

Therapeutic subgroup

L01 - Antineoplastic Agents
L01X

A.T.C. Level 3

Pharmacological subgroup

L01X - Other Antineoplastic Agents in ATC

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

NOT RECOMMENDEDThis item should not be used while operating heavy machinery.

Pregnancy

NOT RECOMMENDEDThis item is not safe for use during pregnancy.

Lactation

NOT RECOMMENDEDThis item is not safe for use during lactation.

Indication

Multiple Myeloma
Bortezomib for injection is indicated for the treatment of Multiple Myeloma patients who have received at least 1 prior therapy and have demonstrated disease progression on the last therapy.
Mantle Cell Lymphoma
Bortezomib for injection is indicated for the treatment of patients with Mantle Cell Lymphoma who have received at least 1 prior therapy.
Multiple Myeloma – Combination therapy
Bortezomib in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated Multiple Myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant.

Dosage

18 YEARS OLD AND ABOVE
Dosage in relapsed multiple myeloma and mantle cell lymphoma.
The recommended dose of bortezomib is 1.3 mg/m²/dose administered as a 3 to 5 second bolus intravenous injection twice weekly for 2 weeks on days 1, 4, 8, and 11, followed by a 10-day rest period on days 12-21. This 3-week period is considered a treatment cycle. At least 72 hours should elapse between consecutive doses of bortezomib. It is recommended that patients receive 2 additional cycles of bortezomib following a confirmation of a complete response. It is also recommended that responding patients who do not achieve a complete remission receive a total of 8 cycles of bortezomib therapy.